Intrust Bank NA acquired a new stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) during the first quarter, according to its most recent filing with the SEC. The fund acquired 1,934 shares of the biopharmaceutical company’s stock, valued at approximately $262,000.
Other large investors also recently added to or reduced their stakes in the company. Xact Kapitalforvaltning AB raised its position in Alexion Pharmaceuticals by 12.3% during the 1st quarter. Xact Kapitalforvaltning AB now owns 41,240 shares of the biopharmaceutical company’s stock valued at $5,575,000 after purchasing an additional 4,507 shares during the last quarter. AJO LP bought a new position in Alexion Pharmaceuticals during the 1st quarter valued at approximately $241,000. AGF Investments Inc. raised its position in Alexion Pharmaceuticals by 11.5% during the 1st quarter. AGF Investments Inc. now owns 5,076 shares of the biopharmaceutical company’s stock valued at $686,000 after purchasing an additional 524 shares during the last quarter. Lido Advisors LLC bought a new position in Alexion Pharmaceuticals during the 1st quarter valued at approximately $287,000. Finally, Swiss National Bank raised its position in Alexion Pharmaceuticals by 2.8% during the 1st quarter. Swiss National Bank now owns 744,641 shares of the biopharmaceutical company’s stock valued at $100,661,000 after purchasing an additional 20,200 shares during the last quarter. Institutional investors own 94.42% of the company’s stock.
ALXN has been the subject of a number of recent analyst reports. BidaskClub raised Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, March 1st. Cowen reissued a “buy” rating and issued a $165.00 target price on shares of Alexion Pharmaceuticals in a research report on Wednesday, March 13th. Guggenheim reissued a “neutral” rating and issued a $135.00 target price on shares of Alexion Pharmaceuticals in a research report on Thursday, March 21st. Royal Bank of Canada reissued an “outperform” rating and issued a $186.00 target price (up previously from $165.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, March 27th. Finally, Raymond James began coverage on Alexion Pharmaceuticals in a research report on Wednesday, April 10th. They issued an “outperform” rating and a $161.00 target price for the company. Six investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. Alexion Pharmaceuticals currently has an average rating of “Buy” and an average target price of $161.06.
Shares of Alexion Pharmaceuticals stock traded up $4.87 during midday trading on Friday, hitting $130.98. The company had a trading volume of 1,468,310 shares, compared to its average volume of 1,525,933. The firm has a 50 day moving average price of $124.21. The company has a quick ratio of 3.36, a current ratio of 3.87 and a debt-to-equity ratio of 0.25. Alexion Pharmaceuticals, Inc. has a 52-week low of $92.56 and a 52-week high of $141.86. The firm has a market cap of $29.37 billion, a PE ratio of 18.47, a P/E/G ratio of 0.94 and a beta of 1.58.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported $2.39 EPS for the quarter, beating the consensus estimate of $1.99 by $0.40. Alexion Pharmaceuticals had a return on equity of 19.53% and a net margin of 9.59%. The business had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same period last year, the business posted $1.68 EPS. The company’s revenue was up 22.5% compared to the same quarter last year. As a group, equities analysts expect that Alexion Pharmaceuticals, Inc. will post 8.61 earnings per share for the current fiscal year.
Alexion Pharmaceuticals Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
Further Reading: What economic reports are most valuable to investors?
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.